gms | German Medical Science

24th Annual Meeting of the German Retina Society

German Retina Society

17.06. - 18.06.2011, Aachen

Guest lecture of the Uveitis section: Intravitreal treatment of macular oedema following uveitis

Meeting Abstract

Search Medline for

  • Lothar Krause - Städtisches Klinikum Dessau

German Retina Society. 24th Annual Conference of the German Retina Society. Aachen, 17.-18.06.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. Doc11rg24

doi: 10.3205/11rg24, urn:nbn:de:0183-11rg243

This is the translated version of the article.
The original version can be found at: http://www.egms.de/de/meetings/rg2011/11rg24.shtml

Published: June 15, 2011

© 2011 Krause.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Cystoid macular oedema is one of the most important reasons of reduced visual acuity in uveitis patients. This guideline describes the use of intravitreal treatment modalities of macular oedema following uveitis including data published in Medline before 30.11.2010. Following subjects has to be considered in the treatment of macular oedema. At first the underlying disease and the intraocular inflammation has to be treated. Is macular oedema persisting following this treatment further medication is necessary. Following a trial with Acetozolamid or extraocular injection of steroids intravitreal treatment should be initiated. With intraviteal injections of Bevacizumab, Ranibizumab, Dexamethason or Triamcinolon visual acuity can be improved. Most data exists for the treatment with Triamcinolon and Bevacizumab. In comparison to steroids VEGF-Inhibitors do not have side effects like glaucoma or cataract and therefore they are the treatment of choice for intravitreal therapy of macular oedema in uveitis patients.